These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2944683)

  • 21. Sex steroid receptors in endometrial cancer.
    Chambers JT
    Yale J Biol Med; 1988; 61(4):339-50. PubMed ID: 3055700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
    Okada H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):924-8. PubMed ID: 2968780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical and histological studies of endometrial carcinoma of the uterus treated with medroxy-progesterone-acetate (author's transl)].
    Ohta M; Takeda A; Ninagawa T; Tomoda Y
    Nihon Gan Chiryo Gakkai Shi; 1980 Dec; 15(7):1098-103. PubMed ID: 6453176
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of long-term high-dose progesterone (Depo-Provera) therapy on endometrial carcinoma].
    Szarvas Z; Zsolnai B; Gimes G; Hidvégi J
    Morphol Igazsagugyi Orv Sz; 1985 Oct; 25(4):253-60. PubMed ID: 2933583
    [No Abstract]   [Full Text] [Related]  

  • 25. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma.
    Satyaswaroop PG; Zaino R; Clarke CL; Mortel R
    J Steroid Biochem; 1987; 27(1-3):431-8. PubMed ID: 2961935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
    Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
    Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
    Ayoub J; Audet-Lapointe P; Méthot Y; Hanley J; Beaulieu R; Chemaly R; Cormier A; Déry JP; Drouin P; Gauthier P
    Gynecol Oncol; 1988 Oct; 31(2):327-37. PubMed ID: 2971597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma.
    Szarvas Z; Zsolnai B
    Acta Chir Hung; 1984; 25(4):269-76. PubMed ID: 6240879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate.
    Quinn MA; Cauchi M; Fortune D
    Gynecol Oncol; 1985 Jul; 21(3):314-9. PubMed ID: 3159630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.
    Rendina GM; Donadio C; Fabri M; Mazzoni P; Nazzicone P
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):285-91. PubMed ID: 6235140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The importance of hormone receptor analysis for diagnosis and therapy of gynecologic malignancies].
    Gitsch E; Salzer H
    Wien Klin Wochenschr; 1983 May; 95(11):385-8. PubMed ID: 6310902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial of progestogens in the primary treatment of endometrial carcinoma.
    Macdonald RR; Thorogood J; Mason MK
    Br J Obstet Gynaecol; 1988 Feb; 95(2):166-74. PubMed ID: 2964861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
    Kline RC; Freedman RS; Jones LA; Atkinson EN
    Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
    [No Abstract]   [Full Text] [Related]  

  • 34. Medroxyprogesterone acetate binding sites in human endometrium and endometrial cancer.
    Ohno Y; Fujibayashi H; Kitagawa I; Fujimoto Y; Okada H
    Gynecol Obstet Invest; 1990; 29(3):227-31. PubMed ID: 2141586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Conservative organ-preserving measures in precancerous stages of endometrial cancer].
    Dallenbach-Hellweg G
    Gynakologe; 1988 Dec; 21(4):302-7. PubMed ID: 2974824
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer.
    Kärkkäinen J; Vesterinen E; Stenman UH; Adlercreutz H; Nieminen U; Widholm O
    Eur J Cancer; 1990; 26(9):975-7. PubMed ID: 2149024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial carcinoma insensitive to progestin and cytotoxic chemotherapy may respond to tamoxifen.
    Kauppila A; Vihko R
    Acta Obstet Gynecol Scand; 1981; 60(6):589-90. PubMed ID: 6461159
    [No Abstract]   [Full Text] [Related]  

  • 38. Determination of hormonal response in uterine cancer cell lines by the ATP bioluminescence assay and flow cytometry.
    Nguyen HN; Sevin BU; Averette HE; Voigt W; Perras J; Angioli R; Ramos R; Donato D; Penalver M
    Gynecol Oncol; 1992 Jul; 46(1):55-61. PubMed ID: 1386055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Basis of gestagen therapy of endometrial carcinoma].
    Trams G
    Dtsch Med Wochenschr; 1978 Mar; 103(13):574-7. PubMed ID: 639688
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytochemical examinations of Ca, cytochrome oxidase and succinate dehydrogenase enzymes in endometrium carcinomatous tissue after high dose progestogen treatment.
    Szarvas Z; Balogh I; Patai K
    Acta Morphol Hung; 1988; 36(3-4):177-83. PubMed ID: 2855777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.